2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess whether GPI 1485 has the ability to delay or stop disease
progression and improve symptoms in patients with Parkinson's disease (PD) that is already
being treated with a dopamine agonist therapy. Whether the drug is working will be assessed
by evaluating clinical endpoints such as UPDRS scores and by evaluating images, obtained by
SPECT scan, of brain activity. Participants in the study will be given either placebo or GPI
1485 treatment. The duration of the study is 2-years and patients are required to complete 12
safety visits and 3 SPECT scans. SPECT scans will be taken before, after 1-year, and after
2-years of treatment with GPI 1485. In completing the SPECT scan, patients will be injected
with a radioactive investigational drug b-CIT and pictures taken using a Single Photon
Emission Computed Tomography (SPECT) camera.